April 22, 1998JAMA

Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial

View Full Paper

Ask AI

Bookmark

Why the study?

Does intravenously administered danaparoid sodium improve favorable outcomes at 3 months in patients with acute ischemic stroke?

Population

1281 persons with acute ischemic stroke enrolled at 36 centers across the United States.

Comparison

7-day course of ORG 10172 given initially as an… vs Placebo given initially as a bolus within 24…

Design

RCT, Randomized, double-blind, placebo-controlled

Follow-up

3 months

Discussion

Member takes

Implication

Danaparoid sodium does not improve 3-month outcomes in acute ischemic stroke; confirms lack of efficacy and supports avoiding use due to bleeding risk.

Structured PICO

Does intravenously administered danaparoid sodium improve favorable outcomes at 3 months in patients with acute ischemic stroke?

Population

1281 persons with acute ischemic stroke enrolled at 36 centers across the United States.

Intervention

7-day course of ORG 10172 (danaparoid sodium) given initially as an intravenous bolus within 24 hours of stroke, followed by continuous infusion (doses adjusted to anti-factor Xa activity) in addition to best medical care.

Comparator

Placebo given initially as a bolus within 24 hours of stroke, followed by continuous infusion for 7 days, in addition to best medical care.

Outcome

Favorable outcome rated as the combination of a Glasgow Outcome Scale score of I or II and a modified Barthel Index of 12 or greater on a scale of 0 to 20 at 3 months.composite

Emergent administration of the antithrombotic agent danaparoid sodium does not improve favorable outcomes at 3 months after acute ischemic stroke and increases the risk of serious intracranial bleeding.

Cite This Study

A 1998 study studied this question.

synapsesocial.com/papers/6a7d67522d005ba2c41cd57a https://doi.org/10.1001/jama.279.16.1265

View Full Paper

Ask AI

Bookmark

Implication

Danaparoid sodium does not improve 3-month outcomes in acute ischemic stroke; confirms lack of efficacy and supports avoiding use due to bleeding risk.

Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Low Molecular Weight Heparinoid, ORG 10172 (Danaparoid), and Outcome After Acute Ischemic Stroke: A Randomized Controlled Trial

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider